GNU Free Documentation License . .

: ,
COMPARISONSLICE HIGH.JPG
() , (), .
-10 G30.30., F00.00.
-9 331.0331.0, 290.1290.1
OMIM 104300 104300
DiseasesDB 490 490
MedlinePlus 000760 000760
eMedicine neuro/13  neuro/13 
MeSH D000544 D000544

( )  , , 1906 . , 65 ,[1]   . 2006 26,6  , 2050 .[2]

-, .[3] .[4] , , , . , , , , - ().[5] , , , (), .[4][6] .[7] - , , . ,[8] .[9]

. .[10] , , . , 2008 , , .[11] , . , , .[12]

, .[13][14]

[]

., , 1901 .

,[15] 1901 , . . 1906 , , , .[16] , « ».[15] , . 1910 , « ».[17]

, 45 65 . 1977 , , , .[18] ,[19] - 65 « » (SDAT), «» . « » , , .[20]

[]

, 100,000  2004 .
            50      5070      7090      90110      110130      130150      150170      170190      190210      210230      230250       250
[21]
65

( )

-
65-69 3
70-74 6
75-79 9
80-84 23
85-89 40
90- 69

, . - ( -), .

( ) 10-15 - 5-8 ,[21][22] . , : 65- , 3 65 69 - 95 .[21][22] , 85 .[22][23]

, , . , . 2000 1.6 % , , 65-74 , . 75-84 19 %, , 84 , 42 %.[24] .[25] , 2005 0.379 % , 2015 0.441 % , 0.556 %, 2030 .[26] .[25] , 2006 0.40 % ( 0.17-0.89 %, 26.6 , 11.4-59.4 ) , , 2050 .[2]

[]

, .

[]

.[4] .[27] .[28] , .[29][30] : , , , ( , ), .[31][32] , .[33][34][35] , «mild cognitive impairment» (MCI)[36], « »[37] « »[38], , .[39]

[]

. , , , ().[40] - . ( ), ( ), ( « » , , , ) .[41][42] , . .[43][44][45] , , , - .[46] , , .[40]

[]

- .[40] , (). .[43][47] , .[48] , .[49] [50] . , , (. sundowning),[51] , , , . 30 % .[33][52] .[53] , - .[40][54]

[]

. , .[43] , .[55] , ,[40] - . , ,[56] .[57] , , .[58][59]

[]

, -.

. « », , . , , , . , , ,[60] .[61]

1991 « », - (Aβ).[62][63] , (APP), -, 21 . , 40 , ( 21 ), - .[64][65] APOE4, , .[66] , , APP, , .[67] , .[68]

.[69] -, -.[63] , - , .[70] ,[71] , .[72]

[]

:
. .

[]

. , , .[61]

, .[10] , - . , , . , , .[73]

[]

- , .

,   ,   - -.[74] 39-43 , - (. A-beta, Aβ). - -  APP. , .[75][76] APP   .[77] - , , , .[10][78]

- .

,   , -. , , , , , . -, , , , . - , - , .[79]

[]

, - .[80] - , . , .[81] , Aβ , .[82]

. , .[83]

[]

, , . APOE, .[84]

10 % 60 - () , 0.01 %.[84][85][86] APP, 1 2,[84] Abeta42, .[87]

, .   E4 APOE, .[88] , - .[84] 400 .[84]   RELN, .[89]

[]

PET- .

( ), ( ), .[90][91] , ,   , - , - .[92] , .[4] . .[93]

[]

(NINDS) .[94] , . , .[95] : , , , , , , , , .

NINCDS-ADRDA, DSM-IV-TR.[96][97]

[]

-, , , , .
-: , B , - (). - .

, , MMSE, , . , .[98][99] , , . , .[4] , .[100] , .[101] .[102] . ,[4] , .[103] , , .[104][105]

SPECT- PET- , .[106] , , SPECT, , , .[107] - B (PiB), . -11 -.[108] , - - .[109] .[4][94]

[]

, , , , - .

, , , . .[110] , ,   , - , ,   . , .[111]

, , , , , , , .[112] , B12, B3, C , ,[113] .[114] , , .[115]

- , , , , ,[116][117] , () .[118][119] .[120] , , , .[121][122] , 2007 , ,[123] .[124]

, , , , , , , .[125][126] .[127]

, ,[128][129] , ,[130][131] .[132] ,[133] .[134][135][136][137]

[]

; , . , .

[]

, , .
, , .

, FDA EMEA,   , NMDA-. , .

.[138] (ACh), ACh, .[139] 2008 , ACh- ,[140] ,[141] ( [142] [143]) ,[144] . .[145] .[146] , , 1-10 % - . , , , , .[147]

, . , , , , , .[148] ,[149] , NMDA-.[148] , , .[150] ,   , , , .[151] « , » .[152]

, , . , , , , .[153][154] .[154]

[]

« »: (. snoezelen) - , .

  • -

, , .[155]

. ,[156] , .[157] , , .[158][159]

, , (reminiscence therapy, RT), , , («»), « » (. simulated presence therapy, SPT). , , .[155] (RT) , , , . RT , .[160] , , . , , SPT, , .[161][162] , , . .[163][164]

, - . , , . , , , . , ,[165][166] , , .[155]

-, , , , . , , , . , .[155]

[]

:

- . .[167] , , , .[168][169][170]

, .

, .[171][172]   , , , .[155][173][174] , .[175] . , , .[176][177] , , .[155]

, , , , , , , . , .[59][178] .[179]

[]

. , , . , , , .[40]

,[8][180][181] .[8] 3 % .[9] , , , , . , , , , , .[180][182][183] , , .[181] , .[9][184]

70 % ,[8] . , .[8][184]

[]

[]

, , .[13][14] , ,[185] ( ),[186] . , .   , , ,   , , .[14] , 160  .,[187]   100  . .[14]

, , , .[13] ,[13] , .[188]

[189] .[188] , , , , , . .[14]

[]

:

,[167] , , , .[168][169][170] , .[190] ,[190][191] .[155]

, , .[192] ,   , , , ,   , , .[193][194] 47 , , . 18000$ 77500$ , .[188][195]

, , , , , .[168][196]

[] , ,

, 1981 . .

, , , ̸. , , .[197][198] [199], - [200], - [201][202], [203], [204], [205], [206].

, «» (2001)[207], , ̸[208]; « » (2004)[209] [210]; « » (« ») (2004)[211]; «» (2005);[212] « » (2006)[213] ;[214] « » (2006), « »[215], «El Internado Laguna Negra»(׸ ; 7 )(2007), « » (2011), « » (2011), « », « » (2011), « » (2011).

, « : » (1999) « : », .[216]

[]

:

2008 400 . III , .[217]

, . , , -, . , . , , , . , , .[218] ACC-001,[219][220] 2008 .[221]   , , - .[222] , , AL-108,[223] - , PBT2.[224] , TNF-, .[225]

, 2008 , , -,[226][227] .[228]

, , - Alzheimer Research Forum.

2000 Folding@home () , , , , II .

[]

  1. Brookmeyer R, Gray S, Kawas C (September 1998). «Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset». Am J Public Health 88 (9): 133742. PMID 9736873.
  2. 1 2 2006 prevalence estimate:
  3. What is Alzheimers disease?. Alzheimers.org.uk (August 2007). 25 2011. 21 2008.
  4. 1 2 3 4 5 6 7 Waldemar G, Dubois B, Emre M, et al (January 2007). «Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline». Eur. J. Neurol. 14 (1): e126. DOI:10.1111/j.1468-1331.2006.01605.x. PMID 17222085.
  5. Alzheimer's diagnosis of AD. Alzheimer's Research Trust. 25 2011. 29 2008.
  6. Tabert MH, Liu X, Doty RL, Serby M, Zamora D, Pelton GH, Marder K, Albers MW, Stern Y, Devanand DP (2005). «A 10-item smell identification scale related to risk for Alzheimer's disease». Ann. Neurol. 58 (1): 155160. DOI:10.1002/ana.20533. PMID 15984022.
  7. Understanding stages and symptoms of Alzheimer's disease. National Institute on Aging (26  2007). 25 2011. 21 2008.
  8. 1 2 3 4 5 Mölsä PK, Marttila RJ, Rinne UK (August 1986). «Survival and cause of death in Alzheimer's disease and multi-infarct dementia». Acta Neurol. Scand. 74 (2): 1037. PMID 3776457. 2008-08-04.
  9. 1 2 3 Mölsä PK, Marttila RJ, Rinne UK (March 1995). «Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia». Acta Neurol. Scand. 91 (3): 15964. PMID 7793228.
  10. 1 2 3 Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J (June 2004). «The importance of neuritic plaques and tangles to the development and evolution of AD». Neurology 62 (11): 19849. PMID 15184601.
  11. Alzheimer's Disease Clinical Trials. US National Institutes of Health. 25 2011. 18 2008.
  12. Can Alzheimer's disease be prevented (pdf). National Institute on Aging (29  2006). 25 2011. 29 2008.
  13. 1 2 3 4 Bonin-Guillaume S, Zekry D, Giacobini E, Gold G, Michel JP (January 2005). «Impact économique de la démence (English: The economical impact of dementia)» (French). Presse Med 34 (1): 3541. ISSN 0755-4982. PMID 15685097.
  14. 1 2 3 4 5 Meek PD, McKeithan K, Schumock GT (1998). «Economic considerations in Alzheimer's disease». Pharmacotherapy 18 (2 Pt 2): 6873; discussion 7982. PMID 9543467.
  15. 1 2 Berchtold NC, Cotman CW (1998). «Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s». Neurobiol. Aging 19 (3): 17389. PMID 9661992.
  16. Auguste D.:
    • Alzheimer Alois (1907). «Über eine eigenartige Erkrankung der Hirnrinde [About a peculiar disease of the cerebral cortex]» ( (.)). Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtlich Medizin 64 (12): 146148.
    • Alzheimer Alois (1987). «About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson)». Alzheimer Dis Assoc Disord 1 (1): 38. PMID 3331112.
    • Maurer Ulrike, Maurer Konrad Alzheimer: the life of a physician and the career of a disease.  New York: Columbia University Press, 2003.  P. 270.  ISBN 0-231-11896-1
  17. Kraepelin Emil, Diefendorf A. Ross (translated by) Clinical Psychiatry: A Textbook For Students And Physicians (Reprint).  Kessinger Publishing.  P. 568.  ISBN 1-4325-0833-4
  18. Katzman Robert, Terry Robert D, Bick Katherine L (editors) Alzheimer's disease: senile dementia and related disorders.  New York: Raven Press, 1978.  P. 595.  ISBN 0-89004-225-X
  19. Boller F, Forbes MM (June 1998). «History of dementia and dementia in history: an overview». J. Neurol. Sci. 158 (2): 12533. PMID 9702682.
  20. Amaducci LA, Rocca WA, Schoenberg BS (November 1986). «Origin of the distinction between Alzheimer's disease and senile dementia: how history can clarify nosology». Neurology 36 (11): 14979. PMID 3531918.
  21. 1 2 3 Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Román GC (January 2008). «Incidence and subtypes of dementia in three elderly populations of central Spain». J. Neurol. Sci. 264 (12): 6372. DOI:10.1016/j.jns.2007.07.021. PMID 17727890.
  22. 1 2 3 Di Carlo A, Baldereschi M, Amaducci L, et al (January 2002). «Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study». J Am Geriatr Soc 50 (1): 418. PMID 12028245.
  23. Andersen K, Launer LJ, Dewey ME, et al (December 1999). «Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group». Neurology 53 (9): 19927. PMID 10599770.
  24. 2000 U.S. estimates:
  25. 1 2 Ferri CP, Prince M, Brayne C, et al (December 2005). «Global prevalence of dementia: a Delphi consensus study» (PDF). Lancet 366 (9503): 21127. DOI:10.1016/S0140-6736(05)67889-0. PMID 16360788. 2008-06-13.
  26. World Health Organization Neurological Disorders: Public Health Challenges.  Switzerland: World Health Organization, 2006.  P. 204207.  ISBN 978-92-4-156336-9
  27. Preclinical: *Linn RT, Wolf PA, Bachman DL, et al (May 1995). «The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort». Arch. Neurol. 52 (5): 48590. PMID 7733843. 2008-08-04.
    • Saxton J, Lopez OL, Ratcliff G, et al (December 2004). «Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset». Neurology 63 (12): 23417. PMID 15623697.
    • Twamley EW, Ropacki SA, Bondi MW (September 2006). «Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease». J Int Neuropsychol Soc 12 (5): 70735. DOI:10.1017/S1355617706060863. PMID 16961952.
  28. Perneczky R, Pohl C, Sorg C, Hartmann J, Komossa K, Alexopoulos P, Wagenpfeil S, Kurz A (2006). «Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues». Age Ageing 35 (3): 240245. DOI:10.1093/ageing/afj054. PMID 16513677.
  29. Arnáiz E, Almkvist O (2003). «Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease». Acta Neurol. Scand., Suppl. 179: 3441. DOI:10.1034/j.1600-0404.107.s179.7.x. PMID 12603249. 2008-06-12.
  30. Kazui H, Matsuda A, Hirono N, et al (2005). «Everyday memory impairment of patients with mild cognitive impairment». Dement Geriatr Cogn Disord 19 (56): 3317. DOI:10.1159/000084559. PMID 15785034. 2008-06-12.
  31. Rapp MA, Reischies FM (2005). «Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE)». American Journal of Geriatric Psychiatry 13 (2): 134141. DOI:10.1176/appi.ajgp.13.2.134. PMID 15703322.
  32. Spaan PE, Raaijmakers JG, Jonker C (2003). «Alzheimer's disease versus normal ageing: a review of the efficiency of clinical and experimental memory measures». Journal of Clinical Experimental Neuropsychology 25 (2): 216233. PMID 12754679.
  33. 1 2 Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP (2005). «A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease». American Journal of Geriatric Psychiatry 13 (6): 460468. DOI:10.1176/appi.ajgp.13.6.460. PMID 15956265.
  34. Robert PH, Berr C, Volteau M, Bertogliati C, Benoit M, Sarazin M, Legrain S, Dubois B (2006). «Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study». Clin Neurol Neurosurg 108 (8): 733736. DOI:10.1016/j.clineuro.2006.02.003. PMID 16567037.
  35. Palmer K, Berger AK, Monastero R, Winblad B, Bäckman L, Fratiglioni L (2007). «Predictors of progression from mild cognitive impairment to Alzheimer disease». Neurology 68 (19): 15961602. DOI:10.1212/01.wnl.0000260968.92345.3f. PMID 17485646.
  36. Small BJ, Gagnon E, Robinson B (April 2007). «Early identification of cognitive deficits: preclinical Alzheimer's disease and mild cognitive impairment». Geriatrics 62 (4): 1923. PMID 17408315.
  37. .. .  : , 2003.  P. 320.  ISBN 5-93486-042-9
  38. .., .. .  : , 2005.  P. 71.
  39. Petersen RC (February 2007). «The current status of mild cognitive impairmentwhat do we tell our patients?». Nat Clin Pract Neurol 3 (2): 601. DOI:10.1038/ncpneuro0402. PMID 17279076.
  40. 1 2 3 4 5 6 Förstl H, Kurz A (1999). «Clinical features of Alzheimer's disease». European Archives of Psychiatry and Clinical Neuroscience 249 (6): 288290. PMID 10653284.
  41. Carlesimo GA, Oscar-Berman M (June 1992). «Memory deficits in Alzheimer's patients: a comprehensive review». Neuropsychol Rev 3 (2): 11969. PMID 1300219.
  42. Jelicic M, Bonebakker AE, Bonke B (1995). «Implicit memory performance of patients with Alzheimer's disease: a brief review». International Psychogeriatrics 7 (3): 385392. DOI:10.1017/S1041610295002134. PMID 8821346.
  43. 1 2 3 Frank EM (September 1994). «Effect of Alzheimer's disease on communication function». J S C Med Assoc 90 (9): 41723. PMID 7967534.
  44. Becker JT, Overman AA (2002). «[The semantic memory deficit in Alzheimer's disease]» (Spanish; Castilian). Rev Neurol 35 (8): 77783. PMID 12402233.
  45. Hodges JR, Patterson K (April 1995). «Is semantic memory consistently impaired early in the course of Alzheimer's disease? Neuroanatomical and diagnostic implications». Neuropsychologia 33 (4): 44159. PMID 7617154.
  46. Benke T (December 1993). «Two forms of apraxia in Alzheimer's disease». Cortex 29 (4): 71525. PMID 8124945.
  47. Forbes KE, Shanks MF, Venneri A (March 2004). «The evolution of dysgraphia in Alzheimer's disease». Brain Res. Bull. 63 (1): 1924. DOI:10.1016/j.brainresbull.2003.11.005. PMID 15121235.
  48. Galasko D, Schmitt F, Thomas R, Jin S, Bennett D (2005). «Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease». Journal of the International Neuropsychology Society 11 (4): 446453. PMID 16209425.
  49. Galasko D, Schmitt F, Thomas R, Jin S, Bennett D (July 2005). «Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease». J Int Neuropsychol Soc 11 (4): 44653. PMID 16209425.
  50. Sartori G, Snitz BE, Sorcinelli L, Daum I (September 2004). «Remote memory in advanced Alzheimer's disease». Arch Clin Neuropsychol 19 (6): 77989. DOI:10.1016/j.acn.2003.09.007. PMID 15288331.
  51. Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A (May 2001). «Sundowning and circadian rhythms in Alzheimer's disease». Am J Psychiatry 158 (5): 70411. PMID 11329390. 2008-08-27.
  52. Neuropsychiatric symptoms: *Scarmeas N, Brandt J, Blacker D, et al (December 2007). «Disruptive behavior as a predictor in Alzheimer disease». Arch. Neurol. 64 (12): 175561. DOI:10.1001/archneur.64.12.1755. PMID 18071039. *Tatsch MF, Bottino CM, Azevedo D, et al (May 2006). «Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity». Am J Geriatr Psychiatry 14 (5): 43845. DOI:10.1097/01.JGP.0000218218.47279.db. PMID 16670248. *Volicer L, Bass EA, Luther SL (October 2007). «Agitation and resistiveness to care are two separate behavioral syndromes of dementia». J Am Med Dir Assoc 8 (8): 52732. DOI:10.1016/j.jamda.2007.05.005. PMID 17931577.
  53. Honig LS, Mayeux R (June 2001). «Natural history of Alzheimer's disease». Aging (Milano) 13 (3): 17182. PMID 11442300.
  54. Gold DP, Reis MF, Markiewicz D, Andres D (January 1995). «When home caregiving ends: a longitudinal study of outcomes for caregivers of relatives with dementia». J Am Geriatr Soc 43 (1): 106. PMID 7806732.
  55. Bär M, Kruse A, Re S (December 2003). «[Situations of emotional significance in residents suffering from dementia]» (German). Z Gerontol Geriatr 36 (6): 45462. DOI:10.1007/s00391-003-0191-0. PMID 14685735.
  56. Souren LE, Franssen EH, Reisberg B (June 1995). «Contractures and loss of function in patients with Alzheimer's disease». J Am Geriatr Soc 43 (6): 6505. PMID 7775724.
  57. Berkhout AM, Cools HJ, van Houwelingen HC (September 1998). «The relationship between difficulties in feeding oneself and loss of weight in nursing-home patients with dementia». Age Ageing 27 (5): 63741. PMID 12675103.
  58. Wada H, Nakajoh K, Satoh-Nakagawa T, et al (2001). «Risk factors of aspiration pneumonia in Alzheimer's disease patients». Gerontology 47 (5): 2716. PMID 11490146.
  59. 1 2 Gambassi G, Landi F, Lapane KL, Sgadari A, Mor V, Bernabei R (July 1999). «Predictors of mortality in patients with Alzheimer's disease living in nursing homes». J. Neurol. Neurosurg. Psychiatr. 67 (1): 5965. PMID 10369823.
  60. Shen ZX (2004). «Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease». Med. Hypotheses 63 (2): 30821. DOI:10.1016/j.mehy.2004.02.031. PMID 15236795.
  61. 1 2 Wenk GL (2003). «Neuropathologic changes in Alzheimer's disease». J Clin Psychiatry 64 Suppl 9: 710. PMID 12934968.
  62. Hardy J, Allsop D (October 1991). «Amyloid deposition as the central event in the aetiology of Alzheimer's disease». Trends Pharmacol. Sci. 12 (10): 38388. PMID 1763432.
  63. 1 2 Mudher A, Lovestone S (January 2002). «Alzheimer's disease-do tauists and baptists finally shake hands?». Trends Neurosci. 25 (1): 2226. PMID 11801334.
  64. Nistor M, Don M, Parekh M, et al (October 2007). «Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain». Neurobiol. Aging 28 (10): 14931506. DOI:10.1016/j.neurobiolaging.2006.06.023. PMID 16904243.
  65. Lott IT, Head E (March 2005). «Alzheimer disease and Down syndrome: factors in pathogenesis». Neurobiol. Aging 26 (3): 38389. DOI:10.1016/j.neurobiolaging.2004.08.005. PMID 15639317.
  66. Polvikoski T, Sulkava R, Haltia M, et al (November 1995). «Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein». N. Engl. J. Med. 333 (19): 124247. PMID 7566000.
  67. Transgenic mice:
    • Games D, Adams D, Alessandrini R, et al (February 1995). «Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein». Nature 373 (6514): 52327. DOI:10.1038/373523a0. PMID 7845465.
    • Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D (September 1996). «Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease». J. Neurosci. 16 (18): 5795811. PMID 8795633. *Hsiao K, Chapman P, Nilsen S, et al (October 1996). «Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice». Science (journal) 274 (5284): 99102. PMID 8810256.
  68. Holmes C, Boche D, Wilkinson D, et al (July 2008). «Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial». Lancet 372 (9634): 21623. DOI:10.1016/S0140-6736(08)61075-2. PMID 18640458.
  69. Schmitz C, Rutten BP, Pielen A, et al (April 2004). «Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease». Am. J. Pathol. 164 (4): 14951502. PMID 15039236.
  70. Goedert M, Spillantini MG, Crowther RA (July 1991). «Tau proteins and neurofibrillary degeneration». Brain Pathol. 1 (4): 27986. PMID 1669718.
  71. Iqbal K, Alonso Adel C, Chen S, et al (January 2005). «Tau pathology in Alzheimer disease and other tauopathies». Biochim. Biophys. Acta 1739 (2-3): 198210. DOI:10.1016/j.bbadis.2004.09.008. PMID 15615638.
  72. Chun W, Johnson GV (2007). «The role of tau phosphorylation and cleavage in neuronal cell death». Front. Biosci. 12: 73356. PMID 17127334.
  73. Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994). «Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital». Cereb. Cortex 4 (2): 13850. PMID 8038565.
  74. Hashimoto M, Rockenstein E, Crews L, Masliah E (2003). «Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases». Neuromolecular Med. 4 (12): 2136. DOI:10.1385/NMM:4:1-2:21. PMID 14528050.
  75. Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J (July 2006). «Synapse formation and function is modulated by the amyloid precursor protein». J. Neurosci. 26 (27): 721221. DOI:10.1523/JNEUROSCI.1450-06.2006. PMID 16822978.
  76. Turner PR, O'Connor K, Tate WP, Abraham WC (May 2003). «Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory». Prog. Neurobiol. 70 (1): 132. PMID 12927332.
  77. Hooper NM (April 2005). «Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein». Biochem. Soc. Trans. 33 (Pt 2): 3358. DOI:10.1042/BST0330335. PMID 15787600.
  78. Ohnishi S, Takano K (March 2004). «Amyloid fibrils from the viewpoint of protein folding». Cell. Mol. Life Sci. 61 (5): 51124. DOI:10.1007/s00018-003-3264-8. PMID 15004691.
  79. Hernández F, Avila J (September 2007). «Tauopathies». Cell. Mol. Life Sci. 64 (17): 221933. DOI:10.1007/s00018-007-7220-x. PMID 17604998.
  80. Van Broeck B, Van Broeckhoven C, Kumar-Singh S (2007). «Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches». Neurodegener Dis 4 (5): 34965. DOI:10.1159/000105156. PMID 17622778.
  81. Yankner BA, Duffy LK, Kirschner DA (October 1990). «Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides». Science (journal) 250 (4978): 27982. PMID 2218531.
  82. Chen X, Yan SD (December 2006). «Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease». IUBMB Life 58 (12): 68694. DOI:10.1080/15216540601047767. PMID 17424907.
  83. Greig NH, Mattson MP, Perry T, et al (December 2004). «New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists». Ann. N. Y. Acad. Sci. 1035: 290315. DOI:10.1196/annals.1332.018. PMID 15681814.
  84. 1 2 3 4 5 Waring SC, Rosenberg RN (March 2008). «Genome-wide association studies in Alzheimer disease». Arch. Neurol. 65 (3): 32934. DOI:10.1001/archneur.65.3.329. PMID 18332245.
  85. Hoenicka J (2006 March 115). «Genes in Alzheimer's disease». Rev Neurol 42 (5): 30205. PMID 16538594.
  86. Campion D, Dumanchin C, Hannequin D, et al (September 1999). «Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum». Am. J. Hum. Genet. 65 (3): 66470. DOI:10.1086/302553. PMID 10441572.
  87. Selkoe DJ (June 1999). «Translating cell biology into therapeutic advances in Alzheimer's disease». Nature 399 (6738 Suppl): A2331. PMID 10392577.
  88. Strittmatter WJ, Saunders AM, Schmechel D, et al (March 1993). «Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease». Proc. Natl. Acad. Sci. USA 90 (5): 197781. PMID 8446617.
  89. Seripa D, Matera MG, Franceschi M, et al (July 2008). «The RELN locus in Alzheimer's disease». J Alzheimers Dis. 14 (3): 33544. PMID 18599960.
  90. Mendez MF (2006). «The accurate diagnosis of early-onset dementia». International Journal of Psychiatry Medicine 36 (4): 401412. PMID 17407994.
  91. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J (November 2006). «Therapeutic approaches to Alzheimer's disease». Brain 129 (Pt 11): 284055. DOI:10.1093/brain/awl280. PMID 17018549.
  92. Dementia: Quick reference guide (PDF). London: (UK) National Institute for Health and Clinical Excellence (November 2006). 25 2011. 22 2008.
  93. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (July 1984). «Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease». Neurology 34 (7): 93944. PMID 6610841.
  94. 1 2 Dubois B, Feldman HH, Jacova C, et al (August 2007). «Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria». Lancet Neurol 6 (8): 73446. DOI:10.1016/S1474-4422(07)70178-3. PMID 17616482.
  95. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF (December 1994). «Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative». Arch. Neurol. 51 (12): 1198204. PMID 7986174.
  96. American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-IV-TR.  4th Edition Text Revision.  Washington DC: American Psychiatric Association, 2000.  ISBN 0890420254
  97. Ito N (May 1996). «[Clinical aspects of dementia]» (Japanese). Hokkaido Igaku Zasshi 71 (3): 31520. PMID 8752526.
  98. Tombaugh TN, McIntyre NJ (September 1992). «The mini-mental state examination: a comprehensive review». J Am Geriatr Soc 40 (9): 92235. PMID 1512391.
  99. Pasquier F (January 1999). «Early diagnosis of dementia: neuropsychology». J. Neurol. 246 (1): 615. PMID 9987708.
  100. Harvey PD, Moriarty PJ, Kleinman L, et al (2005). «The validation of a caregiver assessment of dementia: the Dementia Severity Scale». Alzheimer Dis Assoc Disord 19 (4): 18694. PMID 16327345.
  101. Antoine C, Antoine P, Guermonprez P, Frigard B (2004). «[Awareness of deficits and anosognosia in Alzheimer's disease.]» (French). Encephale 30 (6): 5707. PMID 15738860.
  102. Cruz VT, Pais J, Teixeira A, Nunes B (2004). «[The initial symptoms of Alzheimer disease: caregiver perception]» (Portuguese). Acta Med Port 17 (6): 43544. PMID 16197855.
  103. Clarfield AM (October 2003). «The decreasing prevalence of reversible dementias: an updated meta-analysis». Arch. Intern. Med. 163 (18): 221929. DOI:10.1001/archinte.163.18.2219. PMID 14557220.
  104. Geldmacher DS, Whitehouse PJ (May 1997). «Differential diagnosis of Alzheimer's disease». Neurology 48 (5 Suppl 6): S29. PMID 9153154.
  105. Potter GG, Steffens DC (May 2007). «Contribution of depression to cognitive impairment and dementia in older adults». Neurologist 13 (3): 10517. DOI:10.1097/01.nrl.0000252947.15389.a9. PMID 17495754.
  106. Bonte FJ, Harris TS, Hynan LS, Bigio EH, White CL (July 2006). «Tc-99m HMPAO SPECT in the differential diagnosis of the dementias with histopathologic confirmation». Clin Nucl Med 31 (7): 3768. DOI:10.1097/01.rlu.0000222736.81365.63. PMID 16785801.
  107. Dougall NJ, Bruggink S, Ebmeier KP (2004). «Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia». Am J Geriatr Psychiatry 12 (6): 55470. DOI:10.1176/appi.ajgp.12.6.554. PMID 15545324.
  108. PiB PET:
    • Kemppainen NM, Aalto S, Karrasch M, et al (January 2008). «Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease». Ann. Neurol. 63 (1): 1128. DOI:10.1002/ana.21212. PMID 18023012.
    • Ikonomovic MD, Klunk WE, Abrahamson EE, et al (June 2008). «Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease». Brain 131 (Pt 6): 163045. DOI:10.1093/brain/awn016. PMID 18339640.
    • Jack CR, Lowe VJ, Senjem ML, et al (March 2008). «11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment». Brain 131 (Pt 3): 66580. DOI:10.1093/brain/awm336. PMID 18263627.
  109. Marksteiner J, Hinterhuber H, Humpel C (June 2007). «Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein». Drugs Today 43 (6): 42331. DOI:10.1358/dot.2007.43.6.1067341. PMID 17612711.
  110. Prevention recommendations not supported:
  111. Szekely CA, Breitner JC, Zandi PP (2007). «Prevention of Alzheimer's disease». Int Rev Psychiatry 19 (6): 693706. DOI:10.1080/09540260701797944. PMID 18092245.
  112. Mediterranean diet:
  113. Vitamins prevent:
    • Morris MC, Schneider JA, Tangney CC (2006). «Thoughts on B-vitamins and dementia». J. Alzheimers Dis. 9 (4): 42933. PMID 16917152.
    • Landmark K (2006). «[Could intake of vitamins C and E inhibit development of Alzheimer dementia?]» (Norwegian). Tidsskr. Nor. Laegeforen. 126 (2): 15961. PMID 16415937.
    • Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R (2007). «Relation of higher folate intake to lower risk of Alzheimer disease in the elderly». Arch. Neurol. 64 (1): 8692. DOI:10.1001/archneur.64.1.86. PMID 17210813.
    • Morris MC, Evans DA, Bienias JL, et al (August 2004). «Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline». J. Neurol. Neurosurg. Psychiatr. 75 (8): 10939. DOI:10.1136/jnnp.2003.025858. PMID 15258207.
  114. Vitamins do not prevent:
    • Morris MC, Evans DA, Schneider JA, Tangney CC, Bienias JL, Aggarwal NT (2006). «Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease». J. Alzheimers Dis. 9 (4): 43543. PMID 16917153.
    • Malouf M, Grimley EJ, Areosa SA (2003). «Folic acid with or without vitamin B12 for cognition and dementia». Cochrane Database Syst Rev (4): CD004514. DOI:10.1002/14651858.CD004514. PMID 14584018.
    • Sun Y, Lu CJ, Chien KL, Chen ST, Chen RC (2007). «Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomised, double-blind, placebo-controlled study in Taiwanese patients». Clin Ther 29 (10): 220414. DOI:10.1016/j.clinthera.2007.10.012. PMID 18042476.
    • Boothby LA, Doering PL (2005). «Vitamin C and vitamin E for Alzheimer's disease». Ann Pharmacother 39 (12): 207380. DOI:10.1345/aph.1E495. PMID 16227450.
    • Gray SL, Anderson ML, Crane PK, Breitner JC, McCormick W, Bowen JD, Teri L, Larson E (2008). «Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults». J Am Geriatr Soc 56 (2): 291295. DOI:10.1111/j.1532-5415.2007.01531.x. PMID 18047492.
  115. Curcumin in diet:
    • Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007). «Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model». Journal of Neurochemistry 102 (4): 10951104. DOI:10.1111/j.1471-4159.2007.04613.x. PMID 17472706.
    • Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001). «The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse». Journal of Neuroscience 21 (21): 83708377. PMID 11606625.
  116. Rosendorff C, Beeri MS, Silverman JM (2007). «Cardiovascular risk factors for Alzheimer's disease». Am J Geriatr Cardiol 16 (3): 1439. PMID 17483665.
  117. Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, Sadovnick AD (February 2008). «Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease». CMAJ 178 (5): 54856. DOI:10.1503/cmaj.070796. PMID 18299540.
  118. Reiss AB, Wirkowski E (2007). «Role of HMG-CoA reductase inhibitors in neurological disorders : progress to date». Drugs 67 (15): 211120. PMID 17927279.
  119. Kuller LH (August 2007). «Statins and dementia». Curr Atheroscler Rep 9 (2): 15461. PMID 17877925.
  120. Szekely CA, Breitner JC, Fitzpatrick AL, et al (January 2008). «NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type». Neurology 70 (1): 1724. DOI:10.1212/01.wnl.0000284596.95156.48. PMID 18003940.
  121. Craig MC, Murphy DG (October 2007). «Estrogen: effects on normal brain function and neuropsychiatric disorders». Climacteric 10 Suppl 2: 97104. DOI:10.1080/13697130701598746. PMID 17882683.
  122. Mori K, Takeda M (September 2007). «[Hormone replacement Up-to-date. Hormone replacement therapy and brain function]» (Japanese). Clin Calcium 17 (9): 134954. DOI:CliCa070913491354. PMID 17767023.
  123. Birks J, Grimley Evans J (2007). «Ginkgo biloba for cognitive impairment and dementia». Cochrane Database Syst Rev (2): CD003120. DOI:10.1002/14651858.CD003120.pub2. PMID 17443523. 2008-02-22.
  124. DeKosky ST, Williamson JD, Fitzpatrick AL et al. (2008). «Ginkgo biloba for Prevention of Dementia». Journal of the American Medical Association 300 (19): 22532262. 2008-11-18.
  125. Verghese J, Lipton RB, Katz MJ, et al (June 2003). «Leisure activities and the risk of dementia in the elderly». N. Engl. J. Med. 348 (25): 250816. DOI:10.1056/NEJMoa022252. PMID 12815136.
  126. Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS (2006). «The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study». Lancet Neurol 5 (5): 406412. DOI:10.1016/S1474-4422(06)70417-3. PMID 16632311.
  127. Bialystok E, Craik FIM, Freedman M (2007). «Bilingualism as a protection against the onset of symptoms of dementia». Neuropsychologia 42 (2): 459464. DOI:10.1016/j.neuropsychologia.2006.10.009.
  128. Davanipour Z, Tseng CC, Lee PJ, Sobel E (2007). «A case-control study of occupational magnetic field exposure and Alzheimer's disease: results from the California Alzheimer's Disease Diagnosis and Treatment Centers». BMC Neurol 7: 13. DOI:10.1186/1471-2377-7-13. PMID 17559686.
  129. Qiu C, Fratiglioni L, Karp A, Winblad B, Bellander T (November 2004). «Occupational exposure to electromagnetic fields and risk of Alzheimer's disease». Epidemiology 15 (6): 68794. PMID 15475717. 2008-09-22.
  130. Shcherbatykh I, Carpenter DO (May 2007). «The role of metals in the etiology of Alzheimer's disease». J. Alzheimers Dis. 11 (2): 191205. PMID 17522444.
  131. Rondeau V, Commenges D, Jacqmin-Gadda H, Dartigues JF (July 2000). «Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study». Am. J. Epidemiol. 152 (1): 5966. PMID 10901330.
  132. Kukull WA, Larson EB, Bowen JD, et al (June 1995). «Solvent exposure as a risk factor for Alzheimer's disease: a case-control study». Am. J. Epidemiol. 141 (11): 105971; discussion 10729. PMID 7771442.
  133. Santibáñez M, Bolumar F, García AM (2007). «Occupational risk factors in Alzheimer's disease: a review assessing the quality of published epidemiological studies». Occupational and Environmental Medicine 64 (11): 723732. DOI:10.1136/oem.2006.028209. PMID 17525096.
  134. Seidler A, Geller P, Nienhaus A, et al (February 2007). «Occupational exposure to low frequency magnetic fields and dementia: a case-control study». Occup Environ Med 64 (2): 10814. DOI:10.1136/oem.2005.024190. PMID 17043077.
  135. Rondeau V (2002). «A review of epidemiologic studies on aluminum and silica in relation to Alzheimer's disease and associated disorders». Rev Environ Health 17 (2): 10721. PMID 12222737.
  136. Martyn CN, Coggon DN, Inskip H, Lacey RF, Young WF (May 1997). «Aluminum concentrations in drinking water and risk of Alzheimer's disease». Epidemiology 8 (3): 2816. PMID 9115023.
  137. Graves AB, Rosner D, Echeverria D, Mortimer JA, Larson EB (September 1998). «Occupational exposures to solvents and aluminium and estimated risk of Alzheimer's disease». Occup Environ Med 55 (9): 62733. PMID 9861186.
  138. Geula C, Mesulam MM (1995). «Cholinesterases and the pathology of Alzheimer disease». Alzheimer Dis Assoc Disord 9 Suppl 2: 2328. PMID 8534419.
  139. Stahl SM (2000). «The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action». J Clin Psychiatry 61 (11): 813814. PMID 11105732.
  140. Donepezil. US National Library of Medicine (Medline Plus) (8  2007). 25 2011. 20 2008.
  141. Galantamine. US National Library of Medicine (Medline Plus) (8  2007). 25 2011. 20 2008.
  142. Rivastigmine. US National Library of Medicine (Medline Plus) (8  2007). 25 2011. 20 2008.
  143. Rivastigmine Transdermal. US National Library of Medicine (Medline Plus) (8  2007). 25 2011. 20 2008.
  144. Birks J (2006). «Cholinesterase inhibitors for Alzheimer's disease». Cochrane Database Syst Rev (1): CD005593. DOI:10.1002/14651858.CD005593. PMID 16437532.
  145. Birks J, Harvey RJ (2006). «Donepezil for dementia due to Alzheimer's disease». Cochrane Database Syst Rev (1): CD001190. DOI:10.1002/14651858.CD001190.pub2. PMID 16437430.
  146. Raschetti R, Albanese E, Vanacore N, Maggini M (2007). «Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials». PLoS Med 4 (11): e338. DOI:10.1371/journal.pmed.0040338. PMID 18044984.
  147. Acetylcholinesterase inhibitors prescribing information:
  148. 1 2 Lipton SA (2006). «Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond». Nat Rev Drug Discov 5 (2): 160170. DOI:10.1038/nrd1958. PMID 16424917.
  149. Memantine. US National Library of Medicine (Medline) (4  2004). 25 2011. 22 2008.
  150. Areosa Sastre A, McShane R, Sherriff F (2004). «Memantine for dementia». Cochrane Database Syst Rev (4): CD003154. DOI:10.1002/14651858.CD003154.pub2. PMID 15495043.
  151. Namenda Prescribing Information (PDF). Forest Pharmaceuticals. 25 2011. 19 2008.
  152. Raina P, Santaguida P, Ismaila A, et al (2008). «Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline». Annals of Internal Medicine 148 (5): 379397. PMID 18316756.
  153. Antipsychotics use:
    • Ballard C, Waite J (2006). «The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease». Cochrane Database Syst Rev (1): CD003476. DOI:10.1002/14651858.CD003476.pub2. PMID 16437455.
    • Ballard C, Lana MM, Theodoulou M, et al (2008). «A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)». PLoS Med. 5 (4): e76. DOI:10.1371/journal.pmed.0050076. PMID 18384230.
    • Sink KM, Holden KF, Yaffe K (2005). «Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence». JAMA 293 (5): 596608. DOI:10.1001/jama.293.5.596. PMID 15687315.
  154. 1 2 Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu L-M, Jacoby R (9 January 2009). «The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial». Lancet Neurology. DOI:10.1016/S1474-4422(08)70295-3. PMID 19138567. Lay summary.
  155. 1 2 3 4 5 6 7 Practice Guideline for the Treatment of Patients with Alzheimer's disease and Other Dementias (PDF). American Psychiatric Association (October 2007). doi:10.1176/appi.books.9780890423967.152139. 25 2011. 28 2007.
  156. Bottino CM, Carvalho IA, Alvarez AM, et al (2005). «Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study». Clin Rehabil 19 (8): 861869. DOI:10.1191/0269215505cr911oa. PMID 16323385.
  157. Doody RS, Stevens JC, Beck C, et al (2001). «Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology». Neurology 56 (9): 11541166. PMID 11342679.
  158. Hermans DG, Htay UH, McShane R (2007). «Non-pharmacological interventions for wandering of people with dementia in the domestic setting». Cochrane Database Syst Rev (1): CD005994. DOI:10.1002/14651858.CD005994.pub2. PMID 17253573.
  159. Robinson L, Hutchings D, Dickinson HO, et al (2007). «Effectiveness and acceptability of non-pharmacological interventions to reduce wandering in dementia: a systematic review». Int J Geriatr Psychiatry 22 (1): 922. DOI:10.1002/gps.1643. PMID 17096455.
  160. Woods B, Spector A, Jones C, Orrell M, Davies S (2005). «Reminiscence therapy for dementia». Cochrane Database Syst Rev (2): CD001120. DOI:10.1002/14651858.CD001120.pub2. PMID 15846613.
  161. Peak JS, Cheston RI (2002). «Using simulated presence therapy with people with dementia». Aging Ment Health 6 (1): 7781. DOI:10.1080/13607860120101095. PMID 11827626.
  162. Camberg L, Woods P, Ooi WL, et al (1999). «Evaluation of Simulated Presence: a personalised approach to enhance well-being in persons with Alzheimer's disease». J Am Geriatr Soc 47 (4): 446452. PMID 10203120.
  163. Neal M, Briggs M (2003). «Validation therapy for dementia». Cochrane Database Syst Rev (3): CD001394. DOI:10.1002/14651858.CD001394. PMID 12917907.
  164. Chung JC, Lai CK, Chung PM, French HP (2002). «Snoezelen for dementia». Cochrane Database Syst Rev (4): CD003152. DOI:10.1002/14651858.CD003152. PMID 12519587.
  165. Spector A, Orrell M, Davies S, Woods B (2000). «Withdrawn: Reality orientation for dementia». Cochrane Database Syst Rev (3): CD001119. DOI:10.1002/14651858.CD001119.pub2. PMID 17636652.
  166. Spector A, Thorgrimsen L, Woods B, et al (2003). «Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial». Br J Psychiatry 183: 248254. DOI:10.1192/bjp.183.3.248. PMID 12948999.
  167. 1 2 The MetLife study of Alzheimers disease: The caregiving experience (PDF). MetLife Mature Market Institute (August 2006). 25 2011. 12 2008.
  168. 1 2 3 Thompson CA, Spilsbury K, Hall J, Birks Y, Barnes C, Adamson J (2007). «Systematic review of information and support interventions for caregivers of people with dementia». BMC Geriatr 7: 18. DOI:10.1186/1471-2318-7-18. PMID 17662119.
  169. 1 2 Schneider J, Murray J, Banerjee S, Mann A (August 1999). «EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: IFactors associated with carer burden». International Journal of Geriatric Psychiatry 14 (8): 651661. DOI:<651::AID-GPS992>3.0.CO;2-B 10.1002/(SICI)1099-1166(199908)14:8<651::AID-GPS992>3.0.CO;2-B. PMID 10489656. 2008-07-04.
  170. 1 2 Murray J, Schneider J, Banerjee S, Mann A (August 1999). «EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: II--A qualitative analysis of the experience of caregiving». International Journal of Geriatric Psychiatry 14 (8): 662667. DOI:<662::AID-GPS993>3.0.CO;2-4 10.1002/(SICI)1099-1166(199908)14:8<662::AID-GPS993>3.0.CO;2-4. PMID 10489657.
  171. Gitlin LN, Corcoran M, Winter L, Boyce A, Hauck WW (February 2001). «A randomized, controlled trial of a home environmental intervention: effect on efficacy and upset in caregivers and on daily function of persons with dementia». Gerontologist 41 (1): 414. PMID 11220813. 2008-07-15.
  172. Gitlin LN, Hauck WW, Dennis MP, Winter L (March 2005). «Maintenance of effects of the home environmental skill-building program for family caregivers and individuals with Alzheimer's disease and related disorders». J. Gerontol. A Biol. Sci. Med. Sci. 60 (3): 36874. PMID 15860476.
  173. Treating behavioral and psychiatric symptoms. Alzheimer's Association (2006). 25 2006.
  174. Dunne TE, Neargarder SA, Cipolloni PB, Cronin-Golomb A (2004). «Visual contrast enhances food and liquid intake in advanced Alzheimer's disease». Clinical Nutrition 23 (4): 533538. DOI:10.1016/j.clnu.2003.09.015. PMID 15297089.
  175. Dudek, Susan G. Nutrition essentials for nursing practice.  Hagerstown, Maryland: Lippincott Williams & Wilkins, 2007.  P. 360.  ISBN 0-7817-6651-6
  176. Dennehy C (2006). «Analysis of patients' rights: dementia and PEG insertion». Br J Nurs 15 (1): 1820. PMID 16415742.
  177. Chernoff R (April 2006). «Tube feeding patients with dementia». Nutr Clin Pract 21 (2): 1426. PMID 16556924.
  178. Medical issues:
    • Head B (January 2003). «Palliative care for persons with dementia». Home Healthc Nurse 21 (1): 5360; quiz 61. PMID 12544465.
    • Friedlander AH, Norman DC, Mahler ME, Norman KM, Yagiela JA (September 2006). «Alzheimer's disease: psychopathology, medical management and dental implications». J Am Dent Assoc 137 (9): 124051. PMID 16946428.
    • Belmin J (2007). «Practical guidelines for the diagnosis and management of weight loss in Alzheimer's disease: a consensus from appropriateness ratings of a large expert panel». J Nutr Health Aging 11 (1): 337. PMID 17315078.
    • McCurry SM, Gibbons LE, Logsdon RG, Vitiello M, Teri L (October 2003). «Training caregivers to change the sleep hygiene practices of patients with dementia: the NITE-AD project». J Am Geriatr Soc 51 (10): 145560. PMID 14511168.
    • Perls TT, Herget M (December 1995). «Higher respiratory infection rates on an Alzheimer's special care unit and successful intervention». J Am Geriatr Soc 43 (12): 13414. PMID 7490383.
  179. Shega JW, Levin A, Hougham GW, et al (April 2003). «Palliative Excellence in Alzheimer Care Efforts (PEACE): a program description». J Palliat Med 6 (2): 31520. DOI:10.1089/109662103764978641. PMID 12854952.
  180. 1 2 Bowen JD, Malter AD, Sheppard L, et al (August 1996). «Predictors of mortality in patients diagnosed with probable Alzheimer's disease». Neurology 47 (2): 4339. PMID 8757016.
  181. 1 2 Dodge HH, Shen C, Pandav R, DeKosky ST, Ganguli M (February 2003). «Functional transitions and active life expectancy associated with Alzheimer disease». Arch. Neurol. 60 (2): 2539. PMID 12580712.
  182. Larson EB, Shadlen MF, Wang L, et al (April 2004). «Survival after initial diagnosis of Alzheimer disease». Ann. Intern. Med. 140 (7): 5019. PMID 15068977.
  183. Jagger C, Clarke M, Stone A (January 1995). «Predictors of survival with Alzheimer's disease: a community-based study». Psychol Med 25 (1): 1717. PMID 7792352.
  184. 1 2 Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST (May 2005). «Alzheimer disease and mortality: a 15-year epidemiological study». Arch. Neurol. 62 (5): 77984. DOI:10.1001/archneur.62.5.779. PMID 15883266.
  185. Allegri RF, Butman J, Arizaga RL, et al (August 2007). «Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina». Int Psychogeriatr 19 (4): 70518. DOI:10.1017/S1041610206003784. PMID 16870037.
  186. Suh GH, Knapp M, Kang CJ (August 2006). «The economic costs of dementia in Korea, 2002». Int J Geriatr Psychiatry 21 (8): 7228. DOI:10.1002/gps.1552. PMID 16858741.
  187. Wimo A, Jonsson L, Winblad B (2006). «An estimate of the worldwide prevalence and direct costs of dementia in 2003». Dement Geriatr Cogn Disord 21 (3): 17581. DOI:10.1159/000090733. PMID 16401889.
  188. 1 2 3 Moore MJ, Zhu CW, Clipp EC (July 2001). «Informal costs of dementia care: estimates from the National Longitudinal Caregiver Study». J Gerontol B Psychol Sci Soc Sci 56 (4): S21928. PMID 11445614.
  189. Jönsson L, Eriksdotter Jönhagen M, Kilander L, et al (May 2006). «Determinants of costs of care for patients with Alzheimer's disease». Int J Geriatr Psychiatry 21 (5): 44959. DOI:10.1002/gps.1489. PMID 16676288.
  190. 1 2 Zhu CW, Sano M (2006). «Economic considerations in the management of Alzheimer's disease». Clin Interv Aging 1 (2): 14354. PMID 18044111.
  191. Gaugler JE, Kane RL, Kane RA, Newcomer R (April 2005). «Early community-based service utilization and its effects on institutionalization in dementia caregiving». Gerontologist 45 (2): 17785. PMID 15799982.
  192. Ritchie K, Lovestone S (November 2002). «The dementias». Lancet 360 (9347): 175966. DOI:10.1016/S0140-6736(02)11667-9. PMID 12480441.
  193. Brodaty H, Hadzi-Pavlovic D (September 1990). «Psychosocial effects on carers of living with persons with dementia». Aust N Z J Psychiatry 24 (3): 35161. PMID 2241719.
  194. Donaldson C, Tarrier N, Burns A (April 1998). «Determinants of carer stress in Alzheimer's disease». Int J Geriatr Psychiatry 13 (4): 24856. PMID 9646153.
  195. The MetLife Study of Alzheimers Disease: The Caregiving Experience (PDF). MetLife Mature Market Institute (August 2006). 25 2011. 12 2008.
  196. Pusey H, Richards D (May 2001). «A systematic review of the effectiveness of psychosocial interventions for carers of people with dementia». Aging Ment Health 5 (2): 10719. PMID 11511058.
  197. Garrard P, Maloney LM, Hodges JR, Patterson K (February 2005). «The effects of very early Alzheimer's disease on the characteristics of writing by a renowned author». Brain 128 (Pt 2): 25060. DOI:10.1093/brain/awh341. PMID 15574466.
  198. Sherman FT (September 2004). «Did President Reagan have mild cognitive impairment while in office? Living longer with Alzheimer's Disease». Geriatrics 59 (9): 11, 15. PMID 15461232.
  199. Hungary legend Puskas dies at 79. BBC News (17  2006). 25 2011. 25 2008.
  200. . .. 25 2011. 6 2009.
  201. Prime Ministers in History: Harold Wilson. London: 10 Downing Street. 25 2011. 18 2008.
  202. "Mi padre no reconoció al Rey pero notó el cariño". Madrid: El País (2008). 25 2011. 1 2008.
  203. Peter Falk leidet an Alzheimer (.)
  204. Chicago Rita Hayworth Gala. Alzheimers Association (2007). 25 2011. 25 2008.
  205. Charlton Heston has Alzheimer's symptoms. CNN (9  2002). 25 2011. 25 2008.
  206. Pauli Michelle. Pratchett announces he has Alzheimer's, Guardian News and Media (12  2007). 18 2008.
  207. Iris. IMDB (18  2002). 25 2011. 24 2008.
  208. Bayley John Iris: a memoir of Iris Murdoch.  London: Abacus, 2000.  ISBN 9780349112152
  209. The notebook. IMDB. 25 2011. 22 2008.
  210. Sparks Nicholas The notebook.  Thorndike, Maine: Thorndike Press, 1996.  P. 268.  ISBN 078620821X
  211. Nae meorisokui jiwoogae. IMDB. 25 2011. 2 2011.
  212. Thanmathra. Webindia123.com. 25 2011. 24 2008.
  213. Ashita no kioku. IMDB. 25 2011. 24 2008.
  214. Ogiwara Hiroshi Ashita no Kioku.  Tōkyō: Kōbunsha, 2004.  ISBN 9784334924461
  215. Munro Alice Hateship, Friendship, Courtship, Loveship, Marriage.  New York: A.A. Knopf, 2001.  ISBN 9780375413001
  216. Malcolm and Barbara:
  217. Clinical Trials. Found 459 studies with search of: alzheimer. US National Institutes of Health. 25 2011. 23 2008.
  218. Vaccination:
    • Hawkes CA, McLaurin J (November 2007). «Immunotherapy as treatment for Alzheimer's disease». Expert Rev Neurother 7 (11): 153548. DOI:10.1586/14737175.7.11.1535. PMID 17997702.
    • Solomon B (June 2007). «Clinical immunologic approaches for the treatment of Alzheimer's disease». Expert Opin Investig Drugs 16 (6): 81928. DOI:10.1517/13543784.16.6.819. PMID 17501694.
    • Woodhouse A, Dickson TC, Vickers JC (2007). «Vaccination strategies for Alzheimer's disease: A new hope?». Drugs Aging 24 (2): 10719. PMID 17313199.
  219. Study Evaluating ACC-001 in Mild to Moderate Alzheimers Disease Subjects. Clinical Trial. US National Institutes of Health (11  2008). 25 2011. 5 2008.
  220. Study Evaluating Safety, Tolerability, and Immunogenicity of ACC-001 in Subjects With Alzheimer's Disease. US National Institutes of Health. 25 2011. 5 2008.
  221. Alzheimer's Disease Vaccine Trial Suspended on Safety Concern. Medpage Today (18  2008). 25 2011. 14 2008.
  222. Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease/ Apo_e4 non-carriers. Clinical Trial. US National Institutes of Health (29  2008). 25 2011. 23 2008.
  223. Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment. Clinical Trial. US National Institutes of Health (11  2008). 25 2011. 23 2008.
  224. Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease. Clinical Trial. US National Institutes of Health (13  2008). 25 2011. 23 2008.
  225. Etanercept research:
    • Tobinick E, Gross H, Weinberger A, Cohen H (2006). «TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study». MedGenMed 8 (2): 25. PMID 16926764.
    • Griffin WS (2008). «Perispinal etanercept: potential as an Alzheimer therapeutic». J Neuroinflammation 5: 3. DOI:10.1186/1742-2094-5-3. PMID 18186919.
    • Tobinick E (December 2007). «Perispinal etanercept for treatment of Alzheimer's disease». Curr Alzheimer Res 4 (5): 5502. PMID 18220520.
  226. Wischik Claude M, Bentham Peter, Wischik Damon J, Seng Kwang Meng (July 2008). «Tau aggregation inhibitor (TAI) therapy with remberTM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks». Alzheimer's & Dementia (Alzheimers Association) 4 (4). DOI:10.1016/j.jalz.2008.05.438. 2008-07-30.
  227. Harrington Charles, Rickard Janet E, Horsley David, et al (July 2008). «Methylthioninium chloride (MTC) acts as a Tau aggregation inhibitor (TAI) in a cellular model and reverses Tau pathology in transgenic mouse models of Alzheimer's disease». Alzheimer's & Dementia (Alzheimers Association) 4: T120T121. DOI:10.1016/j.jalz.2008.05.259.
  228. Doody RS, Gavrilova SI, Sano M, et al (July 2008). «Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study». Lancet 372 (9634): 20715. DOI:10.1016/S0140-6736(08)61074-0. PMID 18640457.

[]

:

:

[]


«/w/index.php?title=_&oldid=44155367»